Suppr超能文献

抗炎药物的发现与开发综述:重点应放在前列腺素E的合成还是降解上?

Overview on the Discovery and Development of Anti-Inflammatory Drugs: Should the Focus Be on Synthesis or Degradation of PGE?

作者信息

Mahesh Gopa, Anil Kumar Kotha, Reddanna Pallu

机构信息

Department of Animal Biology, School of Life Sciences, University of Hyderabad, Hyderabad, 500046, India.

出版信息

J Inflamm Res. 2021 Feb 3;14:253-263. doi: 10.2147/JIR.S278514. eCollection 2021.

Abstract

Inflammation is a protective response that develops against tissue injury and infection. Chronic inflammation, on the other hand, is the key player in the pathogenesis of many inflammatory disorders including cancer. The cytokine storm, an inflammatory response flaring out of control, is mostly responsible for the mortality in COVID-19 patients. Anti-inflammatory drugs inhibit cyclooxygenases (COX), which are involved in the biosynthesis of prostaglandins that promote inflammation. The conventional non-steroidal anti-inflammatory drugs (NSAIDs) are associated with gastric and renal side-effects, as they inhibit both the constitutive COX-1 and the inducible COX-2. The majority of selective COX-2 inhibitors (COXIBs) are without gastric side-effects but are associated with cardiac side-effects on long-term use. The search for anti-inflammatory drugs without side-effects, therefore, has become a dream and ongoing effort of the Pharma companies. As PGE is the key mediator of inflammatory disorders, coming up with a strategy to reduce the levels of PGE alone without affecting other metabolites may form a better choice for the development of next generation anti-inflammatory drugs. In this direction the options being explored are on synthesis of PGE-mPGES-1; PGE degradation through a specific PG dehydrogenase, 15-PGDH, and by blocking its activity mediated through a specific PGE receptor, EP4. As leukotrienes formed via the 5-lipoxygenase (5-LOX) pathway also play an important role in the mediation of inflammation, efforts are also being made to target both COX and LOX pathways. This review focuses on addressing the following three points: 1) How NSAIDs and COXIBs are associated with gastric, renal and cardiac side-effects; 2) Should the focus be on the targets upstream or downstream of PGE; and 3) the status of alternative targets being explored for the discovery and development of anti-inflammatory drugs without side-effects.

摘要

炎症是机体针对组织损伤和感染产生的一种保护性反应。另一方面,慢性炎症是包括癌症在内的许多炎症性疾病发病机制中的关键因素。细胞因子风暴是一种失控的炎症反应,是新冠肺炎患者死亡的主要原因。抗炎药物可抑制环氧化酶(COX),该酶参与促进炎症的前列腺素的生物合成。传统的非甾体抗炎药(NSAIDs)会引起胃肠道和肾脏副作用,因为它们同时抑制组成型COX-1和诱导型COX-2。大多数选择性COX-2抑制剂(COXIBs)没有胃肠道副作用,但长期使用会引起心脏副作用。因此,寻找无副作用的抗炎药物已成为制药公司的梦想和不懈努力。由于前列腺素E(PGE)是炎症性疾病的关键介质,制定一种仅降低PGE水平而不影响其他代谢产物的策略可能是开发下一代抗炎药物的更好选择。在这个方向上,正在探索的选择包括合成PGE-微粒体前列腺素E合成酶-1(PGE-mPGES-1);通过特定的前列腺素脱氢酶15-前列腺素脱氢酶(15-PGDH)降解PGE,并通过阻断其由特定的PGE受体EP4介导的活性。由于经由5-脂氧合酶(5-LOX)途径形成的白三烯在炎症介导中也起重要作用,因此也在努力针对COX和LOX途径。本综述着重探讨以下三点:1)NSAIDs和COXIBs如何与胃肠道、肾脏和心脏副作用相关;2)重点应放在PGE的上游还是下游靶点;3)为发现和开发无副作用的抗炎药物而探索的替代靶点的现状。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/248b/7868279/a846d580ee0b/JIR-14-253-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验